Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.
Journal: Digestive diseases and sciences
Published: February 12, 2026
Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk.
Journal: The American journal of gastroenterology
Published: January 26, 2026
Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series.
Journal: Digestive diseases and sciences
Published: October 10, 2025
FUT2 non-secretor status is not associated with disease phenotype or outcomes in patients with Crohn's disease.
Journal: Crohn's & colitis 360
Published: September 29, 2025
Colonic Tissue Expression of MAdCAM-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease.
Journal: Clinical and translational science
Published: August 13, 2025
Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: June 09, 2025
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: April 28, 2025
Food for Thought: EEN as Adjunct Bridge Therapy in Adult Crohn's with Strictures.
Journal: Digestive diseases and sciences
Published: December 08, 2024
Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease.
Journal: Journal of clinical medicine
Published: November 01, 2024
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center.
Journal: Digestive diseases and sciences
Published: October 05, 2024
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: September 06, 2024
Last Updated: 09/26/2026